2023 ABFM Epidemiology review Questions and Answers Correctly verified.
Side effect of denosumab and bisphosphonates - Answer Jaw osteonecrosis
Most
... [Show More] likely to induce remission in Crohn dz - Answer corticosteroids > 5-ASA > infliximab
Bisphosphonates shouldn't be used in pts w/CLCr less than - Answer 35 mL/min/1.73m2
Bisphosphonates use for 5+ years risks... - Answer atypical femoral shaft fractures, recommend drug holiday
Denosumab is safe in CKD because - Answer not cleared by kidneys
IBD diagnosis made via - Answer endoscopy with biopsies
First line for treating DM neuropathy - Answer TCAs (amitriptyline) > SNRI, pregabalin > antiSz
Best management for acute urticaria - Answer second generation X-H1 (longer acting, less drowsy vs 1st gen)
Type of symptoms of depression seen most in elderly - Answer somatic symptoms (also in preg women, children, low income)
Best abx treatment for diabetic foot ulcer - Answer Vanc/Zosyn (Piperacillin/tazobactam) -> covers MRSA, pseudomonas
Percent of wt loss leading to stat-significant improvement of lipid ratios, blood glucose, CAD risk reduction - Answer at least 10%
Most effective weight reduction and long-term maintenance treatment for morbidly obese - Answer bariatric surgery (gastric bypass had mean wt loss 71.2% at 3 year, 20% at 6 years); reduce blood glucose, resolve DMII
Which are some severe CAP symptoms requiring inpatient - Answer confusion, tachypnea, hypotension, multilobar infiltrates (IV ceftriaxone and oral azithromycin)
Outpatient treatment for mild/mod CAP w/out many comorbidities - Answer oral macrolide (azithromycin, clarithromycin, erythromycin) or doxycycline -> add fluoroquins, beta-lactams if comorbidities
Next drug to step up to after albuterol fails to control mild asthma - Answer fluticasone inhaler
Shown to shorten course of Bell's palsy - Answer corticosteroids (antivirals don't do a thing)
Best TB test for immigrants w/bacille Calmette-Guerin (BCG) vaccine - Answer Interferon gamma release assay (QuantiFERON-TB Gold)
... - Answer [Show Less]